Patents by Inventor Cecile Combeau

Cecile Combeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF ANTI-CEACAM5 IMMUNOCONJUGATES FOR TREATING LUNG CANCER
    Publication number: 20220080053
    Abstract: The present disclosure provides methods of treating high CEACAM5 expressing cancers including lung cancers such NSQ NSCLC using immunoconjugates comprising an antibody that specifically binds human CEACAM5.
    Type: Application
    Filed: February 6, 2020
    Publication date: March 17, 2022
    Inventors: Aurore ALLARD, Mustapha CHADJAA, Cécile COMBEAU, Brigitte DEMERS, Christophe HENRY, Semra YORUK
  • Anti-cancer compound and pharmaceutical composition containing the same
    Patent number: 9221817
    Abstract: The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [?]D=?38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in particular a pharmaceutically acceptable acid. The compound is a selective Aurora A and B kinase inhibitor and can be used as an anticancer drug.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: December 29, 2015
    Assignee: SANOFI
    Inventors: Jean-Christophe Carry, Michel Cheve, Francois Clerc, Cecile Combeau, Sylvie Gontier, Alain Krick, Sylvette Lachaud, Laurent Schio
  • ANTI-CANCER COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
    Publication number: 20150266877
    Abstract: The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [?]D=?38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in particular a pharmaceutically acceptable acid. The compound is a selective Aurora A and B kinase inhibitor and can be used as an anticancer drug.
    Type: Application
    Filed: June 2, 2015
    Publication date: September 24, 2015
    Inventors: Jean-Christophe CARRY, Michel CHEVE, Francois CLERC, Cecile COMBEAU, Sylvie GONTIER, Alain KRICK, Sylvette LACHAUD, Laurent SCHIO
  • Anti-cancer compound and pharmaceutical composition containing the same
    Patent number: 9073917
    Abstract: The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [?]D=?38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in particular a pharmaceutically acceptable acid. The compound is a selective Aurora A and B kinase inhibitor and can be used as an anticancer drug.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: July 7, 2015
    Assignee: SANOFI
    Inventors: Jean-Christophe Carry, Michel Cheve, Francois Clerc, Cecile Combeau, Sylvie Gontier, Alain Krick, Sylvette Lachaud, Laurent Schio
  • ANTI-CANCER COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
    Publication number: 20120220621
    Abstract: The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [?]D=?38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in particular a pharmaceutically acceptable acid. The compound is a selective Aurora A and B kinase inhibitor and can be used as an anticancer drug.
    Type: Application
    Filed: May 17, 2010
    Publication date: August 30, 2012
    Applicant: SANOFI
    Inventors: Jean-Christophe Carry, Michel Cheve, Francois Clerc, Cecile Combeau, Sylvie Gontier, Alain Krick, Sylvette Lachaud, Laurent Schio
  • 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
    Patent number: 8163768
    Abstract: This invention relates to compounds of formula (I) to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment comprising administering of such compounds.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: April 24, 2012
    Assignee: Aventis Pharma S.A..
    Inventors: Jacques Mauger, Anil Nair, Nina Ma, Kirsten Bjergarde, Bruno Filoche-Romme, Odile Angouillant-Boniface, Serge Mignani, Jean-Christophe Carry, Francois Clerc, Herve Minoux, Laurent Schio, Cecile Combeau
  • Pyridazinone kinase inhibitors
    Patent number: 7968546
    Abstract: Disclosed are compounds of Formula I wherein X is and R2, R1, A, B, D, E, R9 are as defined herein useful for treating cancers.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: June 28, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Swen Hoelder, Gunter Muller, Karl Schoenafinger, David William Will, Hans Matter, Martin Bossart, Cecile Combeau, Christine Delaisi, Ingrid Sassoon, Anke Steinmetz, Didier Benard
  • 4-benzimidazol-2-ylpyridazin-3-one derivatives
    Patent number: 7754713
    Abstract: Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, R1 and R2 are detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: July 13, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Swen Hoelder, Karl Schoenafinger, David William Will, Hans Matter, Gunter Muller, Cecile Combeau, Christine Delaisi, Anke Steinmetz, Ingrid Sassoon
  • Novel Pyridazinone Derivatives
    Publication number: 20090130209
    Abstract: Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, R1 and R2 are detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).
    Type: Application
    Filed: January 26, 2009
    Publication date: May 21, 2009
    Applicant: Aventis Pharma S.A.
    Inventors: Swen HOELDER, Gunter MULLER, Karl SCHOENAFINGER, David William WILL, Hans MATTER, Martin BOSSART, Cecile COMBEAU, Christine DELAISI, Ingrid SASSOON, Anke STEINMETZ, Didier BENARD
  • Pyridazinone derivatives
    Patent number: 7507734
    Abstract: Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, R1 and R2 are detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: March 24, 2009
    Assignee: Aventis Pharma S.A.
    Inventors: Swen Hoelder, Gunter Muller, Karl Schoenafinger, David William Will, Hans Matter, Martin Bossart, Cecile Combeau, Christine Delaisi, Ingrid Sassoon, Anke Steinmetz, Didier Benard
  • NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES
    Publication number: 20090042880
    Abstract: Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, R1 and R2 are detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).
    Type: Application
    Filed: October 15, 2008
    Publication date: February 12, 2009
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Swen HOELDER, Karl SCHOENAFINGER, David William WILL, Hans MATTER, Gunter MULLER, Cecile COMBEAU, Christine DELAISI, Anke STEINMETZ, Ingrid SASSOON
  • 4-benzimidazol-2-ylpyridazin-3-one derivatives
    Patent number: 7470689
    Abstract: Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, R1 and R2 are detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).
    Type: Grant
    Filed: August 31, 2006
    Date of Patent: December 30, 2008
    Assignee: Aventis Pharma S.A.
    Inventors: Swen Hoelder, Karl Schoenafinger, David William Will, Hans Matter, Günter Müller, Cécile Combeau, Christine Delaisi, Anke Steinmetz, Ingrid Sassoon
  • Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
    Patent number: 7462613
    Abstract: The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl-(C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10-alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.
    Type: Grant
    Filed: November 19, 2003
    Date of Patent: December 9, 2008
    Assignee: SANOFI-AVENTIS Deutschland GmbH
    Inventors: Swen Hölder, Thorsten Naumann, Karl Schönafinger, David William Will, Hans Matter, Günther Müller, Dominique Le Suisse, Bernard Baudoin, Thomas Rooney, Franck Halley, Gilles Tiraboschi, Cécile Combeau, Ingrid Sassoon, Anke Steinmetz
  • 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them
    Publication number: 20080261969
    Abstract: This invention relates to compounds of formula (I) to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment comprising administering of such compounds.
    Type: Application
    Filed: January 15, 2008
    Publication date: October 23, 2008
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Jacques MAUGER, Anil NAIR, Nina MA, Kirsten BJERGARDE, Bruno FILOCHE-ROMME, Odile ANGOUILLANT-BONIFACE, Serge MIGNANI, Jean-Christophe CARRY, Francois CLERC, Herve MINOUX, Laurent SCHIO, Cecile COMBEAU
  • Novel Pyridazinone Derivatives
    Publication number: 20070259870
    Abstract: Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, R1 and R2 are detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).
    Type: Application
    Filed: November 16, 2006
    Publication date: November 8, 2007
    Applicant: Aventis Pharma S.A.
    Inventors: Swen HOELDER, Gunter Muller, Karl Schoenafinger, David Will, Hans Matter, Martin Bossart, Cecile Combeau, Christine Delaisi, Ingrid Sassoon, Anke Steinmetz, Didier Bernard
  • Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives
    Publication number: 20070173503
    Abstract: Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, R1 and R2 are detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals.
    Type: Application
    Filed: August 31, 2006
    Publication date: July 26, 2007
    Applicant: Aventis Pharma S.A.
    Inventors: Swen Hoelder, Karl Schoenafinger, David Will, Hans Matter, Gunter Muller, Cecile Combeau, Christine Delaisi, Anke Steinmetz, Ingrid Sassoon
  • Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology
    Patent number: 7119115
    Abstract: The present invention relates to novel compounds derived from indazoles or indoles of formula (1) or formula (2), to methods for treating tumors or cancerous cells with compounds of formula (1) or formula (2) and to pharmacaetutical compositions comprising a pharmaceutically acceptable carrier and a compound of formula (1) or formula (2)
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: October 10, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Michel Tabart, Eric Bacqué, Sylvie Wentzler, Cécile Combeau, Conception Nemecek, Patrick Mailliet, Fabienne Thompson
  • 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof
    Publication number: 20050203170
    Abstract: 1,3-Diarylprop-2-en-1-ones and derivatives, compositions containing them, manufacturing process and use. Substituted 1,3-diarylprop-2-en-1-ones with therapeutic activity may be used in oncology.
    Type: Application
    Filed: April 19, 2005
    Publication date: September 15, 2005
    Inventors: Patrick Mailliet, Cecile Combeau, Marie-Christine Bissery, Marie-Pierre Cherrier, Thomas Caulfield, Gilles Tiraboschi
  • Compounds derived from oxindoles and their therapeutic application in cancer treatment
    Patent number: 6930124
    Abstract: The invention relates to compounds of formula (I) in which R5 is chosen from the group consisting of: in which R2 is a C1-C3 alkyl group in which X may be Cl, Br, or F in which n is between 1 and 3, in the E or Z form, or a mixture of the two isomeric forms, possessing antimitotic, antiproliferative and antivascular properties through inhibition of the polymerization of tubulin into microtubules
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: August 16, 2005
    Assignee: Aventis Pharma S. A.
    Inventors: Cécile Combeau, Patrick Mailliet, Marielle Chiron
  • Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
    Publication number: 20050026918
    Abstract: The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl-(C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10-alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.
    Type: Application
    Filed: November 19, 2003
    Publication date: February 3, 2005
    Inventors: Swen Holder, Thorsten Naumann, Karl Schonafinger, David Will, Hans Matter, Gunther Muller, Dominique Le Suisse, Bernard Baudoin, Thomas Rooney, Franck Halley, Gilles Tiraboschi, Cecile Combeau, Ingrid Sassoon, Anke Steinmetz